Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
Kris M. White(Icahn School of Medicine at Mount Sinai), Adolfo García‐Sastre(Office of Infectious Diseases), Carles Martínez‐Romero(Icahn School of Medicine at Mount Sinai), Alejandro Losada(PharmaMar (Spain)), Kirsten Obernier(QB3), Nevan J. Krogan(QB3), Marion Déjosez(New York Stem Cell Foundation), Thomas Kehrer(Mental Health Association of Westchester County), Raveen Rathnasinghe(Seqirus (United States)), Elena Moreno(Instituto de Salud Carlos III), Jyoti Batra(Gladstone Institutes), Ajda Rojc(Gladstone Institutes), Mehdi Bouhaddou(QB3), Romel Rosales(Icahn School of Medicine at Mount Sinai), Sonia Jangra(Icahn School of Medicine at Mount Sinai), Lisa Miorin(Columbia University Irving Medical Center), Pablo Avilés(PharmaMar (Spain)), Kevan M. Shokat(Howard Hughes Medical Institute), Thomas P. Zwaka(Baylor College of Medicine), Marco Vignuzzi(Agency for Science, Technology and Research), Soner Yildiz(Icahn School of Medicine at Mount Sinai), Lynda Coughlan(University of Maryland, Baltimore), María José Guillén(PharmaMar (Spain)), Melissa B. Uccellini(Regeneron (United States)), Jacqueline M. Fabius(University of California, San Francisco), Michael Schotsaert(Icahn School of Medicine at Mount Sinai)
Cited by 364
Related Papers
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
|Nature|2013|2.5k
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
|Nature|2010|1.8k
Influenza
|Nature Reviews Disease Primers|2018|1.5k
IRE1 Signaling Affects Cell Fate During the Unfolded Protein Response
|Science|2007|1.4k